{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:44:00Z","timestamp":1782103440596,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T00:00:00Z","timestamp":1203984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1038\/ncpuro1060","type":"journal-article","created":{"date-parts":[[2008,2,26]],"date-time":"2008-02-26T18:12:06Z","timestamp":1204049526000},"page":"211-219","source":"Crossref","is-referenced-by-count":21,"title":["Medical management of lower urinary tract symptoms in men: current treatment and future approaches"],"prefix":"10.1038","volume":"5","author":[{"given":"Anand K","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,26]]},"reference":[{"key":"BFncpuro1060_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","volume":"173","author":"JT Wei","year":"2005","unstructured":"Wei JT et al. (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173: 1256\u20131261","journal-title":"J Urol"},{"key":"BFncpuro1060_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-5347(17)35405-8","volume":"150","author":"CG Chute","year":"1993","unstructured":"Chute CG et al. (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150: 85\u201389","journal-title":"J Urol"},{"key":"BFncpuro1060_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.pcan.4500841","volume":"9","author":"CG Roehrborn","year":"2006","unstructured":"Roehrborn CG et al. (2006) Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 9: 30\u201334","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Suppl 1","key":"BFncpuro1060_CR4","first-page":"S4","volume":"13","author":"MM Issa","year":"2007","unstructured":"Issa MM and Regan TS (2007) Medical therapy for benign prostatic hyperplasia\u2014present and future impact. Am J Manag Care 13 (Suppl 1): S4\u2013S9","journal-title":"Am J Manag Care"},{"key":"BFncpuro1060_CR5","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1314\u20131315","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0022-5347(05)00067-4","volume":"175","author":"H Hashim","year":"2006","unstructured":"Hashim H and Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175: 191\u2013194","journal-title":"J Urol"},{"key":"BFncpuro1060_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"BFncpuro1060_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474\u2013479","journal-title":"J Urol"},{"key":"BFncpuro1060_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0022-5347(17)62763-0","volume":"99","author":"B Lytton","year":"1968","unstructured":"Lytton B et al. (1968) The incidence of benign prostatic obstruction. J Urol 99: 639\u2013645","journal-title":"J Urol"},{"key":"BFncpuro1060_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","volume":"158","author":"SJ Jacobsen","year":"1997","unstructured":"Jacobsen SJ et al. (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158: 481\u2013487","journal-title":"J Urol"},{"key":"BFncpuro1060_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM199802263380901","volume":"338","author":"J McConnell","year":"1998","unstructured":"McConnell J et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338: 557\u2013563","journal-title":"N Engl J Med"},{"key":"BFncpuro1060_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1464-410X.1981.tb03273.x","volume":"53","author":"AJ Ball","year":"1981","unstructured":"Ball AJ et al. (1981) The natural history of untreated \u201cprostatism\u201d. Br J Urol 53: 613\u2013616","journal-title":"Br J Urol"},{"key":"BFncpuro1060_CR13","unstructured":"European Association of Urology Guidelines (2007). Guidelines on benign prostatic hyperplasia [ http:\/\/www.uroweb.org\/fileadmin\/user_upload\/Guidelines\/11%20BPH.pdf ] (accessed 4 February 2008)"},{"key":"BFncpuro1060_CR14","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175: 1422\u20131426","journal-title":"J Urol"},{"key":"BFncpuro1060_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.eururo.2004.07.016","volume":"46","author":"S Madersbacher","year":"2004","unstructured":"Madersbacher S et al. (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46: 547\u2013554","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1464-410X.2004.05022.x","volume":"94","author":"CR Chapple","year":"2004","unstructured":"Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia\/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94: 738\u2013744","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR17","first-page":"143","volume-title":"Male Lower Urinary Tract Dysfunction","author":"C Chapple","year":"2006","unstructured":"Chapple C et al. (2006) New medical developments in the management of LUTS in adult men (World Health Organisation Report\u2014Committee 6). In Male Lower Urinary Tract Dysfunction, 143\u2013194 (Eds McConnel J et al.) Jersey: Health Publications Ltd"},{"key":"BFncpuro1060_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1464-410X.2005.05456.x","volume":"95","author":"J Nordling","year":"2005","unstructured":"Nordling J (2005) Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 95: 1006\u20131012","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","volume":"58","author":"CG Roehrborn","year":"2001","unstructured":"Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58: 953\u2013959","journal-title":"Urology"},{"key":"BFncpuro1060_CR20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1742-1241.1997.tb11460.x","volume":"51","author":"DF Mobley","year":"1997","unstructured":"Mobley DF et al. (1997) Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Int J Clin Pract 51: 282\u2013288","journal-title":"Int J Clin Pract"},{"key":"BFncpuro1060_CR21","first-page":"155","volume":"29","author":"CR Chapple","year":"1996","unstructured":"Chapple CR et al. (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29: 155\u2013167","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.urology.2005.05.001","volume":"66","author":"R MacDonald","year":"2005","unstructured":"MacDonald R and Wilt TJ (2005) Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 66: 780\u2013788","journal-title":"Urology"},{"key":"BFncpuro1060_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(05)65407-9","volume":"167","author":"TJ Wilt","year":"2002","unstructured":"Wilt TJ et al. (2002) Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol 167: 177\u2013183","journal-title":"J Urol"},{"issue":"Suppl 4","key":"BFncpuro1060_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1464-410X.2005.05487.x","volume":"95","author":"MM Barendrecht","year":"2005","unstructured":"Barendrecht MM et al. (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95 (Suppl 4): 19\u201328","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0302-2838(01)00016-1","volume":"41","author":"P van Kerrebroeck","year":"2002","unstructured":"van Kerrebroeck P et al. (2002) Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 41: 54\u201360","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000480808","volume":"32","author":"CR Chapple","year":"1997","unstructured":"Chapple CR et al. (1997) Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 32: 462\u2013470","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0149-2918(97)80097-5","volume":"19","author":"FC Lowe","year":"1997","unstructured":"Lowe FC (1997) Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 19: 730\u2013742","journal-title":"Clin Ther"},{"issue":"Suppl 4","key":"BFncpuro1060_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1464-410X.2005.05486.x","volume":"95","author":"FC Lowe","year":"2005","unstructured":"Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 95 (Suppl 4): 12\u201318","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR29","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","volume":"172","author":"RA Kloner","year":"2004","unstructured":"Kloner RA et al. (2004) Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172: 1935\u20131940","journal-title":"J Urol"},{"key":"BFncpuro1060_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","volume":"31","author":"DF Chang","year":"2005","unstructured":"Chang DF and Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31: 664\u2013673","journal-title":"J Cataract Refract Surg"},{"key":"BFncpuro1060_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eursup.2005.07.006","volume":"4","author":"CR Chapple","year":"2005","unstructured":"Chapple CR (2005) The Oral Controlled Absorption System (OCAS\u00ae): the evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH). Eur Urol Suppl 4: 20\u201322","journal-title":"Eur Urol Suppl"},{"key":"BFncpuro1060_CR32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1464-410X.2004.04765.x","volume":"93","author":"MJ Speakman","year":"2004","unstructured":"Speakman MJ et al. (2004) Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 93: 985\u2013990","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S0090-4295(99)00209-5","volume":"54","author":"R Bruskewitz","year":"1999","unstructured":"Bruskewitz R et al. (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 54: 670\u2013678","journal-title":"Urology"},{"key":"BFncpuro1060_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","volume":"44","author":"GL Andriole","year":"2003","unstructured":"Andriole GL and Kirby R (2003) Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44: 82\u201388","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2490-2-14","volume":"2","author":"JE Edwards","year":"2002","unstructured":"Edwards JE and Moore RA (2002) Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2: 14","journal-title":"BMC Urol"},{"key":"BFncpuro1060_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","volume":"63","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG et al. (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63: 709\u2013715","journal-title":"Urology"},{"key":"BFncpuro1060_CR37","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387\u20132398","journal-title":"N Engl J Med"},{"key":"BFncpuro1060_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","volume":"44","author":"J Barkin","year":"2003","unstructured":"Barkin J et al. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461\u2013466","journal-title":"Eur Urol"},{"key":"BFncpuro1060_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0090-4295(01)01201-8","volume":"58","author":"KC Baldwin","year":"2001","unstructured":"Baldwin KC et al. (2001) Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58: 203\u2013209","journal-title":"Urology"},{"key":"BFncpuro1060_CR40","first-page":"73","volume":"9","author":"SA Kaplan","year":"2007","unstructured":"Kaplan SA and Gonzalez RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9: 73\u201377","journal-title":"Rev Urol"},{"key":"BFncpuro1060_CR41","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/S0022-5347(05)65621-2","volume":"166","author":"S Uckert","year":"2001","unstructured":"Uckert S et al. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484\u20132490","journal-title":"J Urol"},{"key":"BFncpuro1060_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pros.10077","volume":"51","author":"PI Adolfsson","year":"2002","unstructured":"Adolfsson PI et al. (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50\u201358","journal-title":"Prostate"},{"key":"BFncpuro1060_CR43","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1743-6109.2006.00259.x","volume":"3","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP et al. (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3: 662\u2013667","journal-title":"J Sex Med"},{"key":"BFncpuro1060_CR44","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","volume":"177","author":"KT McVary","year":"2007","unstructured":"McVary KT et al. (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401\u20131407","journal-title":"J Urol"},{"key":"BFncpuro1060_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","volume":"177","author":"KT McVary","year":"2007","unstructured":"McVary KT et al. (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071\u20131077","journal-title":"J Urol"},{"key":"BFncpuro1060_CR46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","volume":"51","author":"SA Kaplan","year":"2007","unstructured":"Kaplan SA et al. (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717\u20131723","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"BFncpuro1060_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410X.2005.05484.x","volume":"95","author":"ED Crawford","year":"2005","unstructured":"Crawford ED (2005) Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 95 (Suppl 4): 1\u20135","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR48","unstructured":"GlaxoSmithKline (online 22 December 2004) Study Number: ARI40001 \u2013 Year 1. [ http:\/\/ctr.gsk.co.uk\/Summary\/dutasteride\/studylist.asp ] (Accessed 13 January 2008)"},{"key":"BFncpuro1060_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0090-4295(00)00724-X","volume":"56","author":"S Kaplan","year":"2000","unstructured":"Kaplan S et al. (2000) Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 56: 610\u2013616","journal-title":"Urology"},{"key":"BFncpuro1060_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0022-5347(05)63949-3","volume":"169","author":"C de Nunzio","year":"2003","unstructured":"de Nunzio C et al. (2003) The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 169: 535\u2013539","journal-title":"J Urol"},{"key":"BFncpuro1060_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","volume":"175","author":"P Abrams","year":"2006","unstructured":"Abrams P et al. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999\u20131004","journal-title":"J Urol"},{"key":"BFncpuro1060_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1464-410X.2006.06574.x","volume":"99","author":"BT Blake-James","year":"2007","unstructured":"Blake-James BT et al. (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85\u201396","journal-title":"BJU Int"},{"key":"BFncpuro1060_CR53","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","volume":"174","author":"SA Kaplan","year":"2005","unstructured":"Kaplan SA et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273\u20132275","journal-title":"J Urol"},{"key":"BFncpuro1060_CR54","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"KS Lee","year":"2005","unstructured":"Lee KS et al. (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334\u20131338","journal-title":"J Urol"},{"key":"BFncpuro1060_CR55","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA et al. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319\u20132328","journal-title":"JAMA"},{"key":"BFncpuro1060_CR56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/00029330-200703010-00004","volume":"120","author":"Y Yang","year":"2007","unstructured":"Yang Y et al. (2007) Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120: 370\u2013374","journal-title":"Chin Med J (Engl)"},{"key":"BFncpuro1060_CR57","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2006.07.017","volume":"50","author":"G Novara","year":"2006","unstructured":"Novara G et al. (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50: 675\u2013683","journal-title":"Eur Urol"}],"container-title":["Nature Clinical Practice Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1060","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T20:35:10Z","timestamp":1708634110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpuro1060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,26]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["BFncpuro1060"],"URL":"https:\/\/doi.org\/10.1038\/ncpuro1060","relation":{},"ISSN":["1743-4270","1743-4289"],"issn-type":[{"value":"1743-4270","type":"print"},{"value":"1743-4289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,26]]}}}